Life Insurance Corporation of India (LIC) has increased its shareholding in Cipla Ltd from 7.055% to 9.091% between November 2025 and February 2026. The acquisition was made through open market purchases. This move reflects LIC’s confidence in Cipla’s growth trajectory and strengthens its position as a significant institutional investor.
Life Insurance Corporation of India (LIC), the country’s largest institutional investor, has announced an increase in its stake in Cipla Ltd. According to a regulatory filing, LIC raised its shareholding from 7.055% to 9.091% over the period between November 2025 and February 2026.
Key Highlights
-
Stake Increase: From 7.055% to 9.091%.
-
Mode of Acquisition: Open market purchases.
-
Timeline: November 2025 to February 2026.
-
Strategic Significance: Strengthens LIC’s role as a major institutional investor in Cipla.
-
Industry Context: Cipla, a leading pharmaceutical company, continues to expand its global footprint with a focus on generics, respiratory therapies, and specialty drugs.
-
Investor Confidence: The move signals LIC’s positive outlook on Cipla’s long-term growth and resilience in the pharmaceutical sector.
This development highlights the growing institutional interest in India’s pharmaceutical industry, which remains a critical sector for both domestic healthcare and global exports.
Sources: Company Filing (BSE), Business Standard, Economic Times